These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11892931)

  • 21. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin glulisine. Aventis Pharma.
    Barlocco D
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1240-4. PubMed ID: 14649217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and antibacterial activity of C12 des-methyl ketolides.
    Lin X; Rico AC; Chu DT; Carroll GL; Barker L; Shawar R; Desai MC; Plattner JJ
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4692-6. PubMed ID: 16784845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA; Weaver-Sands DT; Petersen PJ
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical studies of garenoxacin.
    Takagi H; Tanaka K; Tsuda H; Kobayashi H
    Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical basis of macrolides apply in diseases of the respiratory tract].
    Płusa T
    Pol Merkur Lekarski; 2008 Nov; 25(149):432-6. PubMed ID: 19177783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clamikalant (Aventis).
    O'Rourke ST
    IDrugs; 2000 Nov; 3(11):1353-7. PubMed ID: 16047257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-9 Alkenylidine bridged macrolides: WO2008061189. Enanta Pharmaceuticals, Inc.
    Poce G; Cesare Porretta G; Biava M
    Expert Opin Ther Pat; 2009 Jun; 19(6):901-6. PubMed ID: 19473109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is inadequate antibacterial therapy?
    Moellering RC
    Clin Infect Dis; 2009 Oct; 49(7):1006-8. PubMed ID: 19719418
    [No Abstract]   [Full Text] [Related]  

  • 30. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
    Appelbaum PC
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides.
    Denis A; Bretin F; Fromentin C; Bonnet A; Piltan G; Bonnefoy A; Agouridas C
    Bioorg Med Chem Lett; 2000 Sep; 10(17):2019-22. PubMed ID: 10987440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens.
    Schaper KJ; Schubert S; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():3-14. PubMed ID: 16518706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
    Fu H; Marquez S; Gu X; Katz L; Myles DC
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1259-66. PubMed ID: 16343900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial agents: patent highlights July to December 2002.
    Phillips OA
    Curr Opin Investig Drugs; 2003 Feb; 4(2):117-27. PubMed ID: 12669371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the antimicrobial activity of clavulanate.
    Finlay J; Miller L; Poupard JA
    J Antimicrob Chemother; 2003 Jul; 52(1):18-23. PubMed ID: 12775671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The bacteria fight back.
    Taubes G
    Science; 2008 Jul; 321(5887):356-61. PubMed ID: 18635788
    [No Abstract]   [Full Text] [Related]  

  • 37. Whither antibacterial drug discovery?
    Projan SJ
    Drug Discov Today; 2008 Apr; 13(7-8):279-80. PubMed ID: 18405838
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of amino acids as mediators for the antibacterial activity of iodine-lithium-alpha-dextrin in vitro and in vivo.
    Davtyan TK; Hakobyan IS; Muradyan RE; Hovhannisyan HG; Gabrielyan ES
    J Antimicrob Chemother; 2007 Jun; 59(6):1114-22. PubMed ID: 17439975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrolide antibiotics as biological response modifiers.
    Rubin BK; Tamaoki J
    Curr Opin Investig Drugs; 2000 Oct; 1(2):169-72. PubMed ID: 11249569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How can we protect against broad-band pathogens? The situation with quinolone resistance].
    Kresken M; Hafner D
    Pharm Unserer Zeit; 2001; 30(5):436-45. PubMed ID: 11575181
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.